Interestingly, levels of IL-2+CD4+ or CD8+ spike-specific T cells were marginally higher in patients with IBD than in HCs, reaching statistical significance for CD8+ T cells in TNFi+AM-treated patients. This evidence concerns the gene CD4 and inflammatory bowel disease.